RxDoctor Payments Data

Stella Lau

Optometrist · North Las Vegas, NVNPI 1275575722

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Alcon accounts for 93.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $48,852 and has fallen 96.8% since, to $1,542 in 2025. Among optometrist clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$100,042in general payments, 2019–2025

Across 353 payments — averaging $283.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$93K
  • Tarsus Pharmaceuticals, Inc.$3K
  • Glaukos Corporation$1K
  • Bausch & Lomb Americas Inc.$675
  • Sun Pharmaceutical Industries Inc.$493
  • Coopervision Inc.$335
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$50,13450%
  • Speaking & faculty fees$13,20713%
  • Travel & lodging$28,07028%
  • Food & beverage$8,5939%
  • Gifts$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,042 in reported general payments places this provider in the 95th percentile of 494 optometrist providers in Nevada.

See all optometrist providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner15$29,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$3,361$29,30115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 optometrist providers in Nevada.

Other optometrist in North Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →